Antibody-mediated p53 protein therapy prevents liver metastasis in vivo

Cancer Research

Volumn 67, Issue 4, 2007, Pages 1769-1774

  Hansen, James E ^a   Fischer, Laurice K ^b   Chan, Grace ^a   Chang, Sophia S ^a   Baldwin, Scott W ^b,c   Aragon, Robert J ^b,c   Carter, Jacqueline J ^b,c   Lilly, Michael ^c   Nishimura, Robert N ^a,d,e   Weisbart, Richard H ^a,d,f   Reeves, Mark E ^b,c  

^a VA GREATER LOS ANGELES HEALTHCARE SYSTEM   (United States)

^b Jerry L Pettis Memorial VA Medical Center   (United States)

^c LOMA LINDA UNIVERSITY   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HYBRID PROTEIN; MONOCLONAL ANTIBODY; PROTEIN P53;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER PREVENTION; COLON CARCINOMA; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; LIVER METASTASIS; MOUSE; NONHUMAN; PICHIA PASTORIS; PORTAL VEIN; PRIORITY JOURNAL;

ANIMALS; ANTIBODIES, MONOCLONAL; CELL LINE, TUMOR; COLONIC NEOPLASMS; FEMALE; HUMANS; IMMUNOGLOBULIN FRAGMENTS; LIVER NEOPLASMS, EXPERIMENTAL; MICE; MICE, INBRED BALB C; OVARIAN NEOPLASMS; RECOMBINANT FUSION PROTEINS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 33847731392     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-06-3783     Document Type: Article

References (20)

1. Vousden KH. p53: death star. Cell 2000;103:691-4.
2. Nielsen LL, Maneval DC. p53 tumor suppressor gene therapy for cancer. Cancer Gene Ther 1998;5:52-63.
3. Kodama K, Katayama Y, Shoji Y, Nakashima H. The features and shortcomings for gene delivery of current non-viral carriers. Curr Med Chem 2006;13:2155-61.
4. Ryu J, Lee HJ, Kim KA, et al. Intracellular delivery of p53 fused to the basic domain of HIV-1 Tat. Mol Cells 2004;17:353-9.
5. Takenobu T, Tomizawa K, Matsushita M, et al. Development of p53 protein transduction therapy using membrane-permeable peptides and the application to oral cancer cells. Mol Cancer Ther 2002;1:1043-9.
6. Weisbart RH, Hansen JE, Chan G, et al. Antibody mediated transduction of p53 selectively kills cancer cells. Int J Oncol 2004;25:1867-73.
7. El-Amine M, Hinshaw JA, Scott DW. In vivo induction of tolerance by an Ig peptide is not affected by the deletion of FvR or a mutated IgG Fc fragment. Int Immunol 2002;14:761-6.
8. Zambidis ET, Scott DW. 1996 Epitope-specific tolerance induction with an engineered immunoglobulin. Proc Natl Acad Sci U S A 1996;93:5019-24.
9. Lai Y, Du L, Dunsmore KE, Jenkins LW, Wong HR, Clark RS. Selectively increasing inducible heat shock protein 70 via TAT-protein transduction protects neurons from nitrosative stress and excitotoxicity. J Neurochem 2005;94:360-6.
10. Pu H, Tian J, Flora G, et al. HIV-1 Tat protein upregulates inflammatory mediators and induces monocyte invasion into the brain. Mol Cell Neurosci 2003;24:224-37.
11. Moulton HM, Hase MC, Smith KM, Iversen PL. HIV Tat peptide enhances cellular delivery of antisense morpholino oligomers. Antisense Nucleic Acid Drug Dev 2003;13:31-43.
12. Toborek M, Lee YW, Pu H, et al. HIV-Tat protein induces oxidative and inflammatory pathways in brain endothelium. J Neurochem 2003;84:169-79.
13. Weisbart RH, Wakelin R, Chan G, Miller CW, Koeffler PH. Construction and expression of a bispecific single-chain antibody that penetrates mutant p53 colon cancer cells and binds p53. Int J Oncol 2004;25:1113-8.
14. Weisbart RH, Baldwin R, Huh B, Zack DJ, Nishimura R. Novel protein transfection of primary rat cortical neurons using an antibody that penetrates living cells. J Immunol 2000;164:6020-6.
15. Jain A, Slansky JE, Matey LC, Allen HE, Pardoll DM, Schulick RD. Synergistic effect of a granulocyte-macrophage colony-stimulating factor-transduced tumor vaccine and systemic interleukin-2 in the treatment of murine colorectal cancer hepatic metastases. Ann Surg Oncol 2003;10:810-20.
16. Cai SR, Garbow JR, Culverhouse R, et al. A mouse model for developing treatment for secondary liver tumors. Int J Oncol 2005;27:113-20.
17. Kasuya H, Kuruppu HK, Donahue JM, Choi EW, Kawasaki H, Tanabe KK. Mouse models of subcutaneous spleen reservoir for multiple portal venous injections to treat liver malignancies. Cancer Res 2005;65:3823-7.
18. Mehra R, Burtness B. Antibody therapy for early-stage breast cancer: trastuzumab adjuvant and neoadjuvant trials. Expert Opin Biol Ther 2006;6:951-62.
19. Yokota T, Milenic DE, Whitlow M, Schlom J. Rapid tumor penetration of a single-chain Fv and comparison with other immunoglobulin forms. Cancer Res 1992;52:3402-8.
20. Yokota T, Milenic DE, Whitlow M, Wood JF, Hubert SL, Schlom J. Microautoradiographic analysis of the normal organ distribution of radioiodinated single-chain Fv and other immunoglobulin forms. Cancer Res 1993;53:3776-83. Erratum in: Cancer Res 1993;53:5832.